Trials / Terminated
TerminatedNCT05057897
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
Detailed description
The purpose of this study is to demonstrate the immunogenicity and safety of AZD1222, AstraZeneca's approved ChAdOx1 vector vaccine against SARS-CoV-2, in SARS-CoV-2 seronegative immunocompromised individuals who are unvaccinated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AZD1222 | 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6 |
Timeline
- Start date
- 2022-01-31
- Primary completion
- 2023-04-19
- Completion
- 2023-04-19
- First posted
- 2021-09-27
- Last updated
- 2025-01-27
- Results posted
- 2025-01-27
Locations
4 sites across 2 countries: Thailand, Ukraine
Source: ClinicalTrials.gov record NCT05057897. Inclusion in this directory is not an endorsement.